Incyte's topical Jakafi scores again in eczema Phase III; Priority review lines Roche's Tecentriq up for new lung cancer nod
→ Incyte’s ruxolitinib cream — topical formulation of the drug that gave them their cash cow Jakafi — has delivered again in a second Phase III readout. In the TRuE-AD1 trial, as with the previously reported TRuE-AD2, significantly more patients treated with the therapy achieved treatment success as assessed by the investigator at week 8.
The new data show that 50% of patients on the 0.75% dose and 53.8% of those on the 1.5% dose hit the primary endpoint, compared to 15.1% in the control arm (p < 0.0001). In the other, essentially identical trial, the numbers were 39.0%, 51.3% and 7.6%, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
